Company & Leadership | LUTERION Co., Ltd. (루테리온)

Who we are

LUTERION Co., Ltd. is the core intellectual property holder for Luterion™.

LUTERION is building a coordinated development ecosystem around Lu120819 through indication-specific development entities and regional R&D and manufacturing affiliates. This structure enables the group to advance Lu120819 across selected therapeutic areas while maintaining centralized control over core intellectual property, platform strategy, and scientific direction.

Rather than focusing only on downstream disease manifestations, LUTERION's approach is centered on upstream mitochondrial and immune-metabolic biology, where cellular stress, immune dysfunction, and impaired tissue recovery converge.

Core Positioning

IP-holding biotechnology company advancing a mitochondrial-modulating investigational therapeutic platform.

Luterion™ Mitochondrial modulation Host-directed strategy Immune-metabolic biology IP-protected platform

          
          Group structure

One platform. A coordinated group built around it.

LUTERION advances Lu120819 while holding its intellectual property centrally — extending development through affiliated entities dedicated to indication-specific programs and regional infrastructure.

Parent · Core IP holder

LUTERION Co., Ltd.

Owns Luterion™ intellectual property and holds centralized control over platform strategy and scientific direction.

Development

Indication-specific development entities

Advance Lu120819 across selected therapeutic areas.

Infrastructure

Regional R&D & manufacturing affiliates

Translational research, clinical coordination, and GMP-grade IMP manufacturing.

Korea Spain United States Wider Europe

Leadership

Jaekyung Cecilia Song, J.D., Ph.D.

Chief Technology Officer & President

A rare leader who spans science, business, and law — from the development of Lu120819 to the architecture of a global company.

Dr. Song sets LUTERION's scientific and technology direction. Trained at MIT, Boston University, Harvard Medical School, and the University of Cincinnati — and later at Seoul National University Law School — she commands both the science of Lu120819 and the legal and financial architecture of the company built around it.

A former Endowed-Chair Professor and Cancer Institute Director, she now leads the group's strategy end to end — closing multiple fundraises and building affiliated companies worldwide through a therapeutic-area licensing-out (L/O) structure.

Four disciplines · one leader

Science B.S. Biology · MIT

Medicine Harvard (BIDMC) · Boston U · Cincinnati

Law J.D. · Seoul National University

Business Luterion group · global

Credentials

01

B.S., Biology · MIT

02

M.S., Medical Sciences · Boston University School of Medicine

03

Ph.D., Molecular & Cellular Physiology · University of Cincinnati College of Medicine

04

J.D. · Seoul National University

05

Former Endowed-Chair Professor & Cancer Institute Director · Dankook University

06

Laboratory Director · Harvard Medical School (BIDMC)

Building a coordinated development ecosystem around Lu120819.

Contact LUTERION→